WP
Schedule 13D filing
Wynnefield Partners Small Cap Value LP I disclosed a 14.3% stake in LFCR
Wynnefield Partners Small Cap Value LP I reported owning 14.3% of Lifecore Biomedical, Inc. \de\ (LFCR) (5,512,210 shares) in a Schedule 13D filed Sep 29, 2026.
A 13D means the holder may push for changes at the company.
- Disclosed
- Sep 29, 2026
- Source
- Schedule 13D
From a public Schedule 13D, linked above. Not investment advice, and not a recommendation to buy or sell.